Tailoring B cell depletion therapy in MS according to memory B cell monitoring

Conclusion The results of this study show that the memory B cell–based RTX reinfusion protocol is able to reduce the mean number of RTX reinfusions with persistent reduction of disease activity. Classification of evidence This study provides Class IV evidence that for patients with MS, a memory B cell–based RTX reinfusion protocol can reduce the mean number of RTX reinfusions with persistent reduction of disease activity.

http://nn.neurology.org/cgi/content/short/7/5/e845?rss=1

Source: Neurology Neuroimmunology and Neuroinflammation - August 3, 2020 Category: Neurology Authors: Novi, G., Bovis, F., Fabbri, S., Tazza, F., Gazzola, P., Maietta, I., Curro, D., Bruschi, N., Roccatagliata, L., Boffa, G., Lapucci, C., Pesce, G., Cellerino, M., Solaro, C., Laroni, A., Capello, E., Mancardi, G., Sormani, M., Inglese, M., Uccelli, A. Tags: All Immunology, Class IV, Multiple sclerosis Article Source Type: research